...
首页> 外文期刊>Cardiology >Hybrid Revascularization: A Review
【24h】

Hybrid Revascularization: A Review

机译:杂交血运重建:综述

获取原文
获取原文并翻译 | 示例

摘要

Hybrid coronary revascularization (HCR) combines surgical bypass with percutaneous coronary intervention (PCI) performed either during the same procedure or in a staged approach within 60 days. Coronary artery bypass grafting using the left internal mammary artery (LIMA) has shown excellent long-term patency with improved patient survival. It remains the gold standard treatment for the majority of patients with multivessel coronary artery disease. However, saphenous vein grafts have poor long-term patency. Advances in stent technology have resulted in reduced rates of thrombosis and restenosis, making PCI a viable alternative to coronary surgery in selected patients. HCR is attractive as a less invasive method of coronary revascularization which preserves the benefits of the LIMA performed with less invasive surgical techniques with the efficacy of newer generation stents. (C) 2018 S. Karger AG, Basel
机译:混合冠状动脉血运重建术(HCR)将外科搭桥术与经皮冠状动脉介入治疗(PCI)相结合,在同一过程中或在60天内分阶段进行。使用左乳内动脉(LIMA)的冠状动脉旁路移植术显示出良好的长期通畅性,提高了患者的生存率。它仍然是大多数多支冠状动脉疾病患者的金标准治疗方法。然而,大隐静脉移植物的长期通畅性较差。支架技术的进步降低了血栓形成和再狭窄的发生率,使PCI成为选择性患者冠状动脉手术的可行替代方案。HCR作为一种微创的冠状动脉血运重建方法很有吸引力,它保留了采用微创外科技术进行的LIMA的优点,并具有新一代支架的功效。(C) 2018年巴塞尔S.卡格股份公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号